Psychosis

Blister Packs for Several Meds Recalled Due to Risk of Harm to Children

By July 09, 2018

The recall affects approximately 470,000 units that include drugs packaged with 3 to 10 tablets per blister card. The blister packs were developed for use in hospitals, however some were sent to retail pharmacies and were likely dispensed for in-home use.

Atypical Antipsychotic Use and CV Events in Youth: What's the Link?

By July 06, 2018

The retrospective cohort study involved a search of Medicaid claims of pediatric patients aged 5 to 20 years who were initiated on atypical antipsychotic medications.

Aristada Initio Regimen Approved for Initiation of Schizophrenia Treatment

By July 02, 2018

Prior to this approval, the Aristada initiation regimen consisted of taking oral aripiprazole for 21 consecutive days starting with the first Aristada dose.

FDA Approves New Nuplazid Formulation, Dosage Strength

By June 29, 2018

Nuplazid, a non-dopaminergic, selective serotonin inverse agonist, targets 5-HT2A receptors that are thought to be involved in Parkinson's disease psychosis.

Cannabis Use Linked to Psychosis Symptoms in Adolescents

June 19, 2018

These correlations were similar in size to the autoregressive link between PS from ages 15 to 16. There was a statistically significant association for PS at age 15 years with cannabis use at age 16 years.

AMA President Calls Physicians to Lead in Addressing Gun Violence

June 14, 2018

For decades the AMA has demonstrated leadership on this issue, recommending common-sense gun safety precautions, waiting periods and background checks for those wishing to purchase a gun, and increased mental health service funding.

Tobacco Cessation Support Lacking in Mental Health Facilities

May 14, 2018

The researchers found that 48.9% of mental health treatment facilities reported screening patients for tobacco use in 2016; 37.6, 25.2, and 21.5% offered tobacco cessation counseling, nicotine replacement therapy, and non-nicotine tobacco cessation medications, respectively.

Antipsychotic Use and Gestational Diabetes: Is There a Link?

By May 08, 2018

Results showed there was a significant crude risk linked to continuing vs discontinuing certain antipsychotics and developing gestational diabetes; for quetiapine the risk was 7.1% vs 4.1% (adjusted relative risk [ARR] 1.28), respectively; among olanzapine users it was 12% vs 4.7% (ARR 1.61), respectively.

Risk of Pediatric Mental Illness Up After Injury Hospitalization

May 08, 2018

Post-injury, children ages 0 to 4 years with burns were more likely to have mental health diagnoses, after adjustment for race and ethnicity.

Early Intervention Services Best for Early-Phase Psychosis

May 07, 2018

"In early-phase psychosis, EIS are superior to TAU across all meta-analyzable outcomes," the authors write. "These results support the need for funding and use of EIS in patients with early-phase psychosis."

Acadia Addresses Concerns Over Nuplazid Safety in Parkinson's Disease Patients

By April 27, 2018

Concerns over Nuplazid were initially voiced in a CNN article in early April which reported that the drug had been associated with over 700 deaths since its launch in March 2017.

Substance Use Disorders Linked to Conversion to Schizophrenia

April 26, 2018

This prospective cohort study included a population-based sample of 2,539 individuals born in Denmark with an incident diagnosis of schizotypal disorder and without a previous diagnosis of schizophrenia.

Politically-Focused Thoughts, Behaviors Tied to Psychopathology

April 13, 2018

"The findings suggest that politically-focused intrusive thoughts and ritualistic behaviors are associated with psychopathology domains in a manner comparable to general obsessive-compulsive symptoms," the authors write.

Psychosis Could Be a Potential Side Effect of Steroid Treatment in Kids

By April 12, 2018

Iatrogenic steroid-induced psychosis is a rare side effect of glucocorticoid therapy which is mostly seen in adults, although it has been reported in children and adolescents.

Parent-Child Book Reading Tied to Psychosocial Benefits

March 29, 2018

The researchers found that PCBR interventions improved the psychosocial functioning of children and parents compared with controls (standardized mean difference, 0.185).

Pimavanserin Evaluated in Patients With Alzheimer's Disease Psychosis

February 15, 2018

By week 12, for the overall population there was no significant advantage for pimavanserin versus placebo (treatment difference, −0.51; 95% CI, −2.23 to 1.21; P=0.561). Common adverse events in both groups included falls, urinary tract infections, and agitation.

Virtual Reality-Based CBT May Benefit Patients With Psychotic Disorders

February 12, 2018

VR-CBT in addition to standard treatment can reduce paranoid ideation, momentary anxiety

Are Psychiatric Drugs Being Overprescribed in Children and Adolescents?

By January 30, 2018

"Our results show that, at a population level, prescriptions of stimulants and antidepressant medications for children and adolescents do not appear to be prescribed at rates higher than the known rates for psychiatric conditions they are designed to treat," said the study's lead author, Dr. Ryan Sultan.

Specific White Matter Patterns Linked to Youth Psychopathology

January 29, 2018

The feature most associated with both of these traits was a brain white matter pattern reflecting frontotemporal connectivity and crossing fibers in the uncinate fasciculus.

Teen Cannabis Use Linked to Subsequent Psychotic Experiences

January 19, 2018

Risk also increased with early-onset cigarette-only use, but correlation attenuated after adjustment

Number of Adults Seeking Mental Health Specialty Care Increasing

January 12, 2018

The researchers found that between 2008 to 2009 and 2014 to 2015 the number of U.S. adults who received specialty outpatient mental health care rose from 11.3 million to 13.7 million per year/

Is AVATAR Therapy a Viable Treatment for Auditory Hallucinations?

November 27, 2017

The researchers found that 83% of participants met the primary outcome of reduction in auditory verbal hallucinations at 12 weeks, as measured by the total score on the Psychotic Symptoms Rating Scales Auditory Hallucinations (PSYRATS-AH).

FDA Grants Fast Track Status to Lumateperone for Schizophrenia

By November 20, 2017

In two studies, lumateperone showed a statistically significant separation from placebo on the primary endpoint, the Positive and Negative Syndrome Scale, or PANSS, total score.

FDA Approves Antipsychotic Agent With Sensor to Track Ingestion

By November 14, 2017

The product is approved for the treatment of schizophrenia, acute treatment of manic and mixed episodes associated with bipolar I disorder and for use as an add-on treatment for depression in adults.

Long-Term Effects of Valbenazine Examined in Adults With Tardive Dyskinesia

By November 14, 2017

Maintenance of treatment effect was demonstrated with both doses.

Vraylar Approved as Maintenance Treatment for Schizophrenia

By November 13, 2017

Results showed that cariprazine significantly delayed the time to relapse compared to placebo (P=0.0010). A total of 49.5% (n=49/99) of placebo treated patients relapsed vs. 29.7% (n=30/101) for the cariprazine treated patients.

Routine Hypertension Monitoring May Be Necessary With Some Antipsychotics

By November 10, 2017

Antipsychotics used to treat disorders such as schizophrenia, bipolar disorder, and other psychoses mainly involve D2 receptor antagonism and some newer agents target D4 antagonism.

Opinion: How Clinicians Can Help Reduce Firearm-Related Violence

October 18, 2017

Making a public commitment is encouraged as a positive action that physicians can take.

Medication Review Reveals Patient Was on Wrong Drug for 10 Years

By October 13, 2017

The case involved a 69-year old patient with paranoid schizophrenia who was brought to the emergency department following violent behavior against the staff at the nursing facility he resided in.

FDA Rejects Vraylar sNDA for Negative Symptoms of Schizophrenia

By September 25, 2017

In the letter the FDA stated that their preliminary appraisal found that the sNDA was not sufficiently complete to permit a substantive review.